Objective-Vascular smooth muscle cell (VSMC) transformation to an osteochondrogenic phenotype is an initial step toward arterial calcification, which is highly correlated with cardiovascular disease-related morbidity and mortality. TLR2 (Tolllike receptor 2) plays a pathogenic role in the development of vascular diseases, but its regulation in calcification of arteries and VSMCs remains unclear. We postulate that TLR2-mediated inflammation participates in mediating atherosclerotic arterial calcification and VSMC calcification.
C ardiovascular disease remains a major health issue worldwide with significant morbidity and mortality. [1] [2] [3] The main underlying cause of cardiovascular disease is atherosclerosis, which is recognized as a chronic inflammatory disease initiated with endothelial injury followed by immune and proinflammatory cell accumulation, lipid deposition, and progressive inflammatory responses. 4 Morbidity and mortality from atherosclerosis are largely caused by advanced atherosclerotic lesions that result in lesion surface disruption, hematoma or hemorrhage, and thrombotic deposits. Importantly, vascular calcification is a hallmark of advanced atherosclerosis and is highly correlated with clinically significant cardiovascular disease. [1] [2] [3] TLRs (Toll-like receptors) are pattern recognition receptors and play a critical role in regulating inflammatory response and maintaining inflammation homeostasis. 5 Furthermore, inappropriate activation of TLR signaling by pathogenic components and endogenous harmful molecules is implicated in atherosclerosis. 4, 6, 7 It is well known that inflammatory responses in the microenvironment of atherosclerotic lesions induce medial smooth muscle cells migration and proliferation into the intima, which is a key event in the pathophysiology of atherosclerosis. 3, 8 In addition, vascular smooth muscle cell (VSMC) transformation to an osteoblast or a chondrocyte phenotype with loss of contractile markers (SM22α [smooth muscle
protein 22α] and α-SM actin [α-smooth muscle actin]) and induction of osteochondrogenic markers, such as Runx2 (Runtrelated transcription factor 2), osterix, SOX9 (sex-determining region Y-box9), and collagen II is an initial step toward arterial calcification.
1,2,9-12 Despite substantial evidence supporting the pathogenic role of TLRs in the development of arteriosclerotic vascular disease and control of VSMC function, [13] [14] [15] TLR regulation in atherosclerotic vascular calcification remains unclear.
OPG (osteoprotegerin) is a member of the TNF (tumor necrosis factor)-receptor superfamily and acts as a soluble receptor for the RANKL (receptor activator of nuclear factor κB ligand). It is a crucial regulator in bone metabolism and inhibits osteoclastogenesis by blocking RANKL/RANK (receptor activator of nuclear factor κB) signaling. 16, 17 OPG is constitutively produced and secreted by vascular cells including endothelial cells (ECs) and VSMCs. This observation is supported by the fact that OPG is expressed in normal mouse blood vessels, whereas RANKL and RANK are not detected in the arteries of healthy mice. Notably, reduced OPG and increased RANKL and RANK are detected in atherosclerotic lesions and arterial calcification. 16, 18, 19 Furthermore, OPG administration prevents vascular calcification induced by warfarin or vitamin D. 20 These results reveal that OPG has a protective role in vascular calcification. Interestingly, the expression of RANKL and RANK in the calcified arteries of OPG −/− mice are increased, resulting in vascular calcification. 18, 21 RANKL is upregulated and secreted by VSMCs during vascular calcification, and it activates RANK to promote VSMC transdifferentiation in an autocrine/paracrine manner, thereby inducing VSMC calcification. 16, 17 However, the RANKL/ RANK-mediated VSMC transdifferentiation and calcification are inhibited by OPG, suggesting that RANKL/RANK-OPG system is important in regulating VSMC calcification in vascular pathology. 16, 17 In addition, RANKL/RANK-OPG system plays a crucial role in modulating VSMC osteochondrogenic differentiation. 22 The pathophysiological association between the RANKL/RANK-OPG system and TLR2-mediated signaling in VSMCs remains to be determined. Considering the role of inflammation in atherosclerotic progression, including atherosclerosis and atherosclerotic calcification and functional TLR2 promoting inflammation in VSMCs, we postulated that TLR2-mediated inflammation participates in mediating atherosclerotic calcification and VSMC calcification. Our results from in vivo and in vitro analyses reveal that TLR2 activation by agonists promotes VSMC chondrogenic differentiation and consequent calcification, which is mediated via the concerted actions of IL (interleukin)-6-mediated RANKL induction and OPG suppression.
Materials and Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Reagents
Pam2CSK4 (Pam2), Pam3CSK4 (Pam3), zymosan, and HSP60 (heat shock protein 60) were purchased from Invitrogen. U0126 was from InvivoGen. SB203580, PD98059, SP600125, and LY294002 were from Calbiochem. Antibodies for OPG (TA322994; Origene) Runx2 (TA309842; Origene), α-SM actin (A5228; Sigma-Aldrich), SM22α (ab14106; Abcam), osterix (ab22552; Abcam), Collagen II (ab34712; Abcam), SOX9 (sc-20095; Santa Cluz), aggrecan (MA3-16888; Thermo), and β-actin (MAB1501; Millipore) were used in Western blot analysis and Immunohistochemistry.
Induction of Atherosclerosis and Atherosclerotic Calcification in a Mouse Model
Considering that estrous cycles of female animals affect animal behavior and complicate physiology and pathophysiology, we used male mice as the animal material for this study. 
Tlr2
−/− C57BL/6J mice (8-10 weeks old) were randomly fed normal chow or a high-fat, high-cholesterol diet containing 20% fat and 0.12% cholesterol (Research Diets incorporation D12108Ci) for 8 or 20 weeks. This method followed the guidelines of experimental atherosclerosis studies described in the American Heart Association Statement. 23 After this, the mice were killed, and blood samples were collected for cytokine analysis. The aortas were harvested for analysis of atherosclerotic lesion and calcification. To be more specific in terms of the measurement of the chondrogenic and calcific area in mouse lesion sites from the ascending aorta to the end of the arch, we made three 3-µm sections on each slide, with a total of 100 slides in a sequential manner. We picked 1 slide from every 10 slides and 10 slides for each group to perform Alizarin Red S (ARS) and Alcian blue staining. The mouse experiments were approved by the Institutional Animal Care and Use Committee, National Health Research Institutes.
Cell Culture and Treatment
Primary VSMCs were isolated from 18.5-day postconception embryonic mouse aortas of C57BL/6J mice (The National Laboratory Animal Center, Taipei, Taiwan) and Tlr2 −/− C57BL/6J mice (The Jackson Laboratory) and cultured in a growth medium containing DMEM supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 μg/mL) as previously described. 13 Cells were passaged every 3 to 5 days, and experiments were performed on cells 6 to 8 passages after the primary culture. There was no significant change in expression of α-SM actin, myocardin, and vimentin in VSMCs after 6 to 8 passages ( Figure I in the online-only Data Supplement), indicating that these cells had the same phenotype.
VSMCs were preincubated with or without inhibitors for 30 minutes before treatment with endotoxin-free Tris-EDTA (TE) buffer, TLR2 ligands (0.1 μg/mL Pam2CSK4, 1 μg/mL Pam3CSK4, To investigate the effect of IL-6, RANKL, and OPG on TLR2 ligand-induced or LPS-induced VSMC calcification and chondrogenesis, VSMCs were treated with TLR2 ligands or LPS together with or without rat-IgG (2.5 μg/mL), anti-IL-6 (2.5 μg/mL) antibodies (eBioscience), recombinant proteins IL-6, RANKL, and OPG (R&D) for the indicated time.
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Specific ELISA
IL-6 levels in the culture supernatants and plasma were determined in microtiter plates (96-well) by a specific sandwich ELISA (14-7061-85 and 13-7062-85; eBioscience) as previously described. 24, 25 OPG and RANKL in the culture supernatants were measured using an OPG-(ab100733; Abcam; or DY459; R&D) and RANKL-(ab100749; Abcam) specific detection ELISA Kit with a 96-well microtiter plate according to the manufacturer's instructions.
Western Blot Analysis
Cellular proteins extracted from VSMCs were resolved with 4% to 12% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. They were blotted with specific antibodies as previously described.
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Calcification Assay
Aortas of ApoE −/− and ApoE −/− Tlr2 −/− mice were perfused with saline and immersed in 10% formalin for 24 hours at room temperature and then directly stained with ARS (Sigma-Aldrich). Aorta tissue blocks were dehydrated in a graded series of ethanol, embedded in paraffin, cut into 3 µm-thick serial sections, and stained with ARS for detecting vascular calcification. Staining was performed with 1% ARS in ddH 2 O for 5 minutes at room temperature. After staining, the aortas and aortic sections were washed 3× with ddH 2 O, and images were acquired on Olympus E-330 camera with ED 50 mm f2.0 Macro lens. The ARS-stained tissue was analyzed using ImageJ software. The percentage of tissue area with ARS nodules was calculated by dividing the ARS nodule area by the total area of the aorta.
To assess VSMC calcification, WT and Tlr2 −/− VSMCs were treated with different treatments in a calcifying medium for the indicated time. VSMC calcification was determined by ARS staining. In brief, VSMCs were washed in PBS and fixed with 2% paraformaldehyde in PBS for 15 minutes. The wells were washed 3× with PBS and stained with 1% ARS in ddH 2 O for 5 minutes at room temperature. The plates were then rinsed 3× with ddH 2 O and observed under a light microscope for calcified nodules. To quantify ARS contents, ARS nodules were extracted using 10% acetic acid or cetylpyridinium chloride and measured their absorbance at 450 or 560 nm using an ELISA reader.
Calcium Detection
VSMC calcified nodules were decalcified with 0.6 N HCl at 4°C for 16 hours, and calcium contents in HCl solution were measured by the O-Cresophtalein method using a calcium detection kit (ab102505; Abcam) according to the manufacturer's instructions.
Chondrogenesis Assay
The paraffin-embedded aortic tissues and paraformaldehyde-fixed VSMCs were stained with 1% Alcian blue (Sigma-Aldrich) dissolved in 3% acetic acid for 3 hours at room temperature and then washed 3× with 3% acetic acid. The staining images were acquired on Olympus XI71 microscope and DP70 camera. The Alcian blue areas in the aortic section were quantified using ImageJ software and expressed as the percent positive area out of the total tissue area. For quantitative analysis of Alcian blue in VSMCs, the Alcian blue was extracted with 10% SDS, and absorbance at 650 nm was measured using an ELISA reader.
Immunohistochemistry
Before immunohistochemical detection of OPG, Runx2, SOX9, osterix, collagen II, and aggrecan in aortic sections, the sections were deparaffinized with xylene and progressively rehydrated through graded alcohols. Antigen sites were retrieved by heating the sections on slides in an EDTA antigen retrieval buffer of pH 8 (Trilogy; Cell Marque Corporation) in an electric pressure cooker for 10 minutes. Sections were sequentially blocked by 3% H 2 O 2 for 20 minutes and blocking buffer (5% BSA in phosphate-buffered saline with 0.1% Tween 20 [PBST]) for additional 30 min. All antibodies described hereafter were diluted in PBS. Sections were incubated at room temperature for 2 hours or 4 o C for 16 hours with primary antibody and then washed in PBST. The sections were then incubated with HRP Labelled Polymer (Dako) for 60 minutes and washed 3× with PBST. OPG, Runx2, SOX9, osterix, collagen II, aggrecan, and RANKL were visualized using the DAB Chromogen system (Dako). To validate the specificity of positive staining, a negative control representing staining with an irrelevant isotype control antibody and secondary antibodies alone was used ( Figure II in the online-only Data Supplement). Tissues were counterstained with hematoxylin. The immunopositive areas in the aorta tissues were quantified using ImageJ software. The signal values were expressed as the percent positive area out of the total tissue area, which was first subtracted by negative staining values and then normalized to the total area.
Statistical Analysis
In vitro data were represented as means±SD and in vivo data as means±SEM. T test was used to determine the statistical significance of difference between treatment and control groups, whereas 1-way ANOVA was used to analyze multiple groups. However, normality of the distribution and equal variance were tested before using t test or 1-way ANOVA. F test and Bartlett test were performed to validate equal variance, whereas Kolmogorov-Smirnov and D'Agostino and Pearson omnibus tests were used for normality. If data with normal distribution did not show equal variance, Welch t test and Games-Howell test were further used to examine the significance. For appropriate 2-factor analysis, validating significance of data in 2 genotypes with different operations was achieved by Bonferroni post hoc test. P values of <0.05 were considered statistically significant.
Results
TLR2 Deficiency Prevents High-Fat Diet-Induced Atherosclerotic Calcification in ApoE −/− Mice
Vascular calcification triggered by inflammatory signals is a pathophysiological feature of advanced atherosclerosis with reducing elasticity and compliance of the vessel wall. 11 TLR2 has been reported to play an important role in regulating atherosclerosis, 13, 27 but its regulation in vascular calcification remains to be investigated. Consistent with previous reports, 27 ApoE −/− mice fed a high-fat diet (HFD) for 8 weeks induced atherosclerotic plaque. This can be prevented in OPG has been shown to inhibit vascular calcification. 18, 20 We hypothesized that feeding HFD induces atherosclerotic calcification by activating TLR2-mediated suppression of OPG expression. We, therefore, evaluated the OPG expression in aortic sections of ApoE −/− and ApoE −/− Tlr2 −/− mice fed an HFD for 20 weeks. To confirm that OPG is suppressed by HFD in vivo, we determined OPG expression in murine aorta by immunohistochemical examination. OPG staining was mainly detected in VSMCs of normal aorta, which diminished after HFD treatment ( Figure 1D and Figure VIA in the online-only Data Supplement). A significant decrease in immunopositive areas for OPG and VSMC differentiation markers, SM22α, and α-SM actin in the atherosclerotic lesions ( Figure 1D ) was found to be highly associated with enhanced neointimal calcification in the atherosclerotic lesion of HFD-fed mice ( Figure 1A , 1B, and 1D). Quantitative analysis confirmed significant downregulation of OPG in the arterial intima and media and SM22α and α-SM actin in the media (not neointima) of HFD-fed ApoE 
Tlr2
−/− mice. Furthermore, VSMC transdifferentiation is associated with vascular calcification.
9,10 Therefore, we reasoned that TLR2-mediated vascular calcification modulates OPG production in VSMCs. To confirm the presence of OPG in the conditioned medium (CM) of VSMCs (VSMC-CM), we analyzed the CM by ELISA and detected comparable amounts of OPG in VSMC-CM and a smaller amount in EC-CM ( Figure VIC in the online-only Data Supplement). However, OPG could not be detected in fresh medium containing FBS. These results indicate that OPG is expressed not only in VSMCs but also in arterial ECs. Furthermore, vascular OPG is mainly derived from VSMCs. Activation of TLR2 by its ligand Pam3 significantly reduced the protein levels of α-SM actin and SM22α in WT VSMCs, which was accompanied by a reduction in OPG production ( Figure 1F-1G ). These TLR2-mediated downregulations of OPG, SM22α, and α-SM actin in WT VSMCs were prevented in Tlr2 −/− VSMCs ( Figure 1F-1G ), suggesting that TLR2-mediated downregulation of VSMC OPG may result in VSMC calcification which then contributes to vascular calcification.
TLR2 Activation Promotes VSMC Calcification In Vitro
Because VSMC calcification is a predominant pathophysiological feature of atherosclerotic calcification and TLR2 deficiency in mice inhibited HFD-induced atherosclerotic calcification, we next asked whether TLR2 plays a significant role in VSMC calcification. To address this query, VSMCs were exposed to control or TLR2 agonists in a calcifying medium for 3 to 6 weeks, with medium changes every 3 days. The calcification occurred in a time-dependent manner in WT VSMCs cultured in the calcifying medium (Figure 2A) . Activation of TLR2 and TLR4 by their ligands time-dependently promoted calcification and total calcium content in WT VSMC when compared with the control (medium alone) and TE buffer (Figure 2A and 2B and Figure VII in the online-only Data Supplement). We posited whether TLR2 is involved in Pam3-induced VSMC calcification. VSMC calcification promoted by Pam3, but not LPS, was suppressed in Tlr2 −/− VSMCs ( Figure 2C ). Furthermore, TLR2 deficiency suppressed Pam3-induced total calcium content in VSMC but had no effect on LPS-induced total calcium content ( Figure 2D ). These data indicated that activating TLR2 aggravates VSMC calcification.
To investigate whether TLR2-mediated VSMC calcification is attributable to the secretion of soluble molecules, VSMCs were cultured with CM from VSMCs treated with TE buffer, Pam3, or LPS for 3 weeks and refreshed with CM at 3-day intervals. To perform this study, we first examined whether 100% CM from VSMCs treated with Pam3 or LPS for 3 days still contained Pam3 or LPS. After this, the 100% CM was fractionated according to size (<3 kDa and >3 kDa) into protein fraction and small molecular fraction. The small molecular filtrates (<3 kDa, Pam3 CM filtrate or LPS CM filtrate) were collected and were used to treat VSMCs. A high concentration of IL-6 was detected in 
Decreased OPG Secretion With Increasing IL-6-Mediated RANKL Secretion Is Necessary for TLR2-Induced VSMC Calcification
As TLR2 deficiency prevented vascular calcification and VSMC calcification accompanied by restoring OPG secretion by VSMCs (Figure 1E) , we evaluated the effect of recombinant OPG on the calcific activity of Pam3 and LPS. VSMC calcification induced by Pam3 or LPS was inhibited by exogenous recombinant mouse OPG ( Figure 2F ), suggesting that a decrease in OPG release is involved in VSMC calcification triggered by Pam3 or LPS.
OPG is shown to act as a soluble decoy receptor for RANKL, which can promote VSMC calcification through RANK-BMP4 (bone morphogenetic protein 4)-dependent signaling.
16,17 Therefore, we determined whether RANKL secretion by Pam3-treated VSMCs participates in VSMC calcification. The RANKL level in CM from VSMCs treated with Pam3 was significantly increased, compared with that in CM from VSMCs treated with TE buffer. Pam3-induced RANKL level was suppressed by TLR2 deficiency ( Figure 2G ). In addition, OPG-mediated suppression of Pam3-induced VSMC calcification was abrogated by exogenous recombinant mouse RANKL in a dose-dependent manner ( Figure 2H and Figure  X in the online-only Data Supplement). These results indicated that TLR2-induced RANKL secretion contributes to VSMC calcification. TLR2 deficiency suppressed HFD-induced atherosclerotic calcification ( Figure 1A and 1B) and decreased HFDinduced plasma IL-6 level ( Figure 1C) . Furthermore, TLR2 agonists-induced IL-6 production in WT VSMCs was abrogated in Tlr2 −/− VSMCs ( Figure 3A) . Therefore, we investigated whether IL-6 is a soluble factor released into the CM that promotes VSMC calcification. IL-6, but not IL-12, neutralizing antibodies significantly inhibited VSMC calcification induced by Pam3-CM or LPS-CM. However, this inhibitory effect was restored by exogenous recombinant mouse IL-6 ( Figure 3B) . As IL-6 has been reported to regulate RANKL expression in VSMCs, 22 we next determined whether Pam3-and LPS-modulated productions of RANKL and OPG are mediated via IL-6 production and secretion. The results revealed that RANKL level in Pam3-CM and LPS-CM was reduced by anti-IL-6 antibodies, but not control IgG ( Figure 3C ). IL-6 antibodies did not affect the OPG level in Pam3-CM and LPS-CM ( Figure 3D ). Moreover, exogenous recombinant mouse OPG had no effect on TLR2-mediated production of IL-6 and RANKL ( Figure 3E and 3F). These results suggest that TLR2 concurrently triggered IL-6-meditated RANKL production and reduced OPG secretion to induce VSMC calcification.
TLR2 Activation Promotes VSMC Chondrogenic Differentiation
Vascular calcification reflects a cellular osteochondrogenic transformation, which is associated with an increased expression of osteochondrogenic proteins. Osteoblastic marker Runx2 was reported to be upregulated in HFD-mediated calcified atherosclerotic plaques of ApoE −/− mice, 28 but its induction was not affected in ApoE Figure 4D ). These results suggest that HFD activates TLR2 to promote cellular chondrogenic differentiation through the induction of osterix, SOX9, and collagen II, and this subsequently resulted in atherosclerotic calcification.
To further investigate whether TLR2 activation triggers VSMC chondrogenic differentiation, VSMCs were treated with Pam3 or LPS in a calcifying medium for 1 to 4 weeks. VSMC chondrogenesis was then assessed by Alcian blue staining. Pam3 and LPS induced VSMC chondrogenesis within 1 week and lasted for at least 4 weeks compared with TE buffer (Figure 5A ). However, TLR2 deficiency abrogated VSMC chondrogenesis induced by Pam3, but not LPS. Furthermore, other TLR2 ligand Pam2 induced WT, but not Tlr2 −/− VSMC chondrogenesis ( Figure 5B ). These data indicate that TLR2 participates in VSMC chondrogenesis.
Given that Pam3 and LPS significantly decreased OPG production and secretion in VSMC-CM and induced VSMC calcification that was attenuated by exogenous recombinant OPG (Figures 1F and 2F) , we evaluated the effect of recombinant OPG on VSMC chondrogenic transdifferentiation. Exogenous recombinant mouse OPG dose-dependently suppressed VSMC chondrogenesis induced by Pam3 or LPS ( Figure 5C and Figure XIIA in the online-only Data Supplement). Furthermore, Pam3-and LPS-mediated inhibition of VSMC markers SM22α and α-SM actin was reduced by OPG in a dose-dependent manner ( Figure 5D and Figure  XIIB in the online-only Data Supplement). These results suggest that OPG in the extracellular milieu plays a key role in regulating VSMC chondrogenic transdifferentiation mediated by TLR2 agonist or TLR4 agonist.
In addition to OPG, the involvement of IL-6-mediated RANKL in regulating VSMC calcification has been demonstrated above. We then evaluated whether IL-6 signaling participates in VSMC chondrogenesis. The results revealed that VSMC chondrogenesis induced by Pam3 or LPS was significantly abrogated by anti-IL-6 but not anti-IL-12 antibodies ( Figure 5E and Figure XIIC in the online-only Data Supplement). The reduced expression of SM α-actin and SM22α induced by Pam3 were restored by anti-IL-6 antibodies ( Figure XIID in the online-only Data Supplement). Taken together, these results suggest that the induction of IL-6-mediated RANKL secretion and reduction of OPG production are essential for TLR2 activation-mediated and TLR4 activation-mediated VSMC chondrogenesis.
Involvement of Signaling Kinases in TLR2-Mediated VSMC Chondrogenesis
Signaling kinases, including p38 MAPK (mitogen-activated protein kinase), ERK1/2, JNK (c-Jun N terminal kinase), and PI3K/Akt (phosphoinositide-3 kinase/protein kinase B) have or without rat-IgG (2.5 μg/mL), anti-IL-6 (2.5 μg/mL), anti-IL-12 (2.5 μg/mL) antibodies, or IL-6 (100 ng/mL) for 3 wk. VSMC calcification and quantification of calcium deposition was performed as in Figure 2A . C, RANKL and (D) OPG (osteoprotegerin) level in CM from VSMCs treated with Pam3 or LPS with or without rat-IgG (2.5μg/mL) and anti-IL-6 (2.5 μg/mL) antibodies for 3 d were measured by ELISA. E and F, VSMCs were treated with TE buffer, Pam3, or LPS in calcifying medium with different amounts of OPG for 3 d. E, IL-6 and (F) RANKL level in culture supernatants were measured by ELISA. Data in A-F represent mean±SD of at least 3 independent experiments. been reported to be involved in TLR2-and TLR4-induced signaling and responses. 29 Our results have shown that Pam3, but not vehicle control, strongly induced the phosphorylation of p38 MAPK, ERK1/2, JNK1/2, AKT, and NF-κB (nuclear factor κB) p65 within 10 minutes and lasted for at least 40 minutes in WT VSMCs, but not in online-only Data Supplement) were similar to those of these inhibitors on Pam3-induced VSMC chondrogenesis and IL-6 production. Taken together, these results indicated that VSMC chondrogenesis and IL-6 secretion induced by Pam3 or LPS are mediated by the concerted actions of p38 MAPK and ERK1/2 signaling. We next investigated whether these 2 kinases were also involved in RANKL induction and OPG suppression because IL-6-mediated RANKL induction and OPG suppression participated in Pam3-and LPS-induced VSMC chondrogenesis ( Figure 5 ). Inhibitors of these 2 kinases all potently suppressed RANKL production induced by Pam3 ( Figure 6C ). Pretreating VSMCs with U0126 or SB203580 alone slightly decreased constitutive OPG expression in VSMCs ( Figure 6D and Figure XIVE in the onlineonly Data Supplement), but inhibition of ERK1/2 by U0126 significantly abrogated Pam3-and LPS-mediated decrease of OPG levels in VSMC-CM ( Figure 6D and Figure XVC in the online-only Data Supplement). However, SB203580 had no significant effect ( Figure XIVE and XVC in the online-only Data Supplement). These results suggest that basal activity of ERK1/2 and p38 in VSMCs may be involved in constitutive OPG expression, whereas the induced ERK1/2 activation, but not the induced p38, participates in Pam3-and LPS-mediated decrease of VSMC OPG production. Activation of NF-κB mediated by MAPK kinase activity is known to play an important role in the regulation of numerous genes involved in the inflammatory response and control of cell function. 29 We thus evaluated the effect of NF-κB inhibitor JSH23 on VSMC chondrogenesis, OPG suppression, and induction of IL-6 and RANKL induction. JSH23 significantly blocked Pam3-and LPS-induced VSMC chondrogenesis and IL-6 and RANKL production, as well as decreased OPG suppression in the VSMCs ( Figure 6E-6H and Figure XVI in the online-only Data Supplement) without affecting VSMC viability ( Figure  XIVB in the online-only Data Supplement). Collectively, these results imply that Pam3 and LPS may activate p38 MAPK and ERK1/2 signaling to coordinately trigger NF-κB-mediated IL-6 production, thereby inducing RANKL production, whereas Pam3-and LPS-mediated decreases in OPG production were elicited via the activation of ERK1/2-mediated NF-κB signaling. These signaling pathways subsequently coordinate an additive augmentation of VSMC chondrogenesis.
Discussion
Innate immune receptors, TLRs, were demonstrated to play a critical role in regulating vascular inflammation and vascular cellular homeostasis. 4, 6 Despite much evidence indicating that TLR2 and TLR4 deficiency prevent mice from HFD-induced atherosclerotic plaque formation through the control of cellular phenotypic function of ECs, macrophages, and VSMCS, 4, 6, 7 their effect on atherosclerotic calcification remains unclear. In this study, we used ApoE −/− Tlr2 −/− mice and found that TLR2 deficiency prohibits atherosclerotic plaque formation in short-term (8 weeks) HFD feeding but does not prevent the formation of atherosclerotic plaques in long-term HFD-fed mice (20 weeks) . This suggests that TLR2 deficiency may prevent or delay pathological initiation and processing of HFD-induced atherosclerosis. Long-term HFD-induced atherosclerosis is mediated by other atherosclerotic signalings, such as TLR4 signaling. We showed that the long-term HFDfed ApoE −/− mice developed intimal vascular calcification with chondrogenic metaplasia and downregulation of OPG, α-SM actin, and SM22α as well as upregulation of osterix, SOX9, and collagen II within atherosclerotic lesions. Notably, these HFD-induced advance atherosclerotic pathologies are prevented in ApoE −/− Tlr2 −/− mice. Furthermore, we found that TLR2 activation drives VSMC calcification and VSMC chondrogenic transdifferentiation by coordinate regulation of IL-6-mediated RANKL production and downregulated OPG production. Our results provide new insights into the mechanism underlying TLR2-induced VSMC calcification and differentiation.
OPG derived by ECs and VSMCs is implicated in regulating EC physiology and VSMC phenotypic plasticity, thereby modulating vascular calcification. 16, 17 Growing evidence suggests that OPG deficiency results in osteoporosis and arterial calcification. 18 Our findings indicate that TLR2 deficient mice restore HFD-mediated reduction in aortic OPG expression, which concurrently prevents atherosclerotic calcification with chondrogenic metaplasia. Although conventional MAPKs were reported to be involved in VSMC OPG expression, [30] [31] [32] little is known about the regulation of TLR2-modulated OPG expression in VSMC. In the present study, we demonstrated that ligand-activated TLR2 drives ERK1/2 and NF-κB signaling to block VSMC OPG production and consequently induces VSMC calcification. Furthermore, TLR2 agonist-mediated VSMC chondrogenesis and calcification are abolished by TLR2 deficiency and OPG treatment. To the best of our knowledge, our results show that activating TLR2 promotes VSMC chondrogenic transformation and calcification by suppressing OPG production, which is mediated via ERK1/2 and NF-κB -dependent signaling. Supporting our findings, it has been shown that these 2 signaling pathways are required for the suppression of OPG in cells upon extracellular stimulation. [30] [31] [32] OPG acts as a RANKL decoy receptor that prevents RANKL interaction with its receptor RANK and exerts an opposite biological effect of RANKL-mediated VSMC phenotypic transformation and calcification. 16, 17, 22 In accordance with the accumulating evidence indicating that upregulated RANKL and downregulated OPG in VSMCs are concomitant with VSMC osteochondrogenic differentiation and calcification, our results indicate that TLR2 agonist oppositely regulates the expression of RANKL and OPG in VSMCs, upregulating RANKL and downregulating OPG. Taken together, TLR2 activation induces VSMC chondrogenesis and calcification via an imbalance in the RANKL/OPG ratio or RANKL/RANK/OPG signaling.
In addition to OPG, OPN (osteopontin) has been reported to play a crucial role in vascular calcification and VSMC function. However, its role in vascular calcification remains controversial. [33] [34] [35] [36] Evidence indicates that OPN is divided into 2 distinct isoforms (secreted OPN and intracellular OPN) with substantially different biological functions. Although TLR2 and TLR4 can control these 2 OPN isoforms' expressions, 37 the pathophysiological interaction between OPN and TLRmediated VSMC calcification remains to be further elucidated.
IL-6 is thought to be a proatherogenic factor which plays a key role in inducing VSMC migration and proliferation. [13] [14] [15] 38 Accumulating evidence suggests that IL-6 can mediate RANKL induction, and it can act as a regulator of VSMC calcification. 22, 39 Our previous study reported that ligand-activated TLR2 promotes VSMC migration through CREB (cAMP response element-binding protein)-mediated IL-6 production signaled via p38 MAPK and ERK1/2. 13 Here, we further demonstrate that TLR2 activation by agonists selectively induces IL-6-dependent VSMC chondrogenesis and calcification, which is mediated via p38 MAPK and ERK1/2 pathways leading to NF-κB activation and NF-κB-dependent IL-6 production. The TLR2 ligand-induced IL-6, in turn, mediates RANKL production but has no effect on OPG production, suggesting that the IL-6-RANKL signaling in part participates in TLR2-mediated chondrogenesis and calcification of VSMCs. Furthermore, plasma IL-6 levels in HFD-fed ApoE −/− mice with atherosclerotic calcification is suppressed
